Please click here to log in with you RCPsych web account details; you will be redirected back to CPD Online.If you have forgotten your College web account details, you will be able to reset them here.
Please click here to log in if your institution has a subscription to CPD Online with Athens access.
Please click here to log in if you are subscribed through Medicom Netherlands.
If you having troubles signing in with the options above, please try this alternative login route.
by Dr Sumeet Gupta and
Dr Udayan Khastgir
Last reviewed: September 2020
Lithium is an established treatment for
bipolar disorder and an augmenting agent for depression. Despite
evidence for its effectiveness, many other mood-stabilising drugs
are preferred to lithium because of concerns about its adverse
effects (including renal adverse effects) and toxicity.
Among those taking lithium, renal adverse effects are common,
but it is difficult to predict which patients are likely to develop
them. Hence, regular monitoring is essential to identify and manage
This module will help you understand how to monitor and
interpret different renal parameters, especially the estimated
glomerular filtration rate (eGFR) and the albumin/creatinine ratio
(ACR), so as to manage renal adverse effects. You will learn about
the risks and benefits of lithium continuation or discontinuation
in patients developing renal impairment.
This module provides an overview of the renal adverse effects of
taking lithium, but focuses on chronic kidney disease (CKD) in
prescribing: initiation and monitoring by Dr Ekta Sharma, Dr
Tayeem Pathan and Dr Stuart Adams
The pharmacological management of mania by Dr
Karine A.N. Macritchie and Professor Allan H. Young
The pharmacological treatment of resistant
depression – an overview by Professor Philip J. Cowen
Related Advances articles
Download take-home notes to print and